Bunkerhill ECG-EF vs ASSURE Wearable ECG
AI Verdict
Choose Bunkerhill ECG-EF if…
Choose Bunkerhill ECG-EF if your primary goal is to rapidly screen a broad patient population for early indicators of heart failure risk using existing 12-lead ECG data. This tool is ideal for integrating into routine clinical workflows to non-invasively identify patients with reduced left ventricular ejection fraction (LVEF), aiding in timely intervention.
View Bunkerhill ECG-EF →Choose ASSURE Wearable ECG if…
Choose ASSURE Wearable ECG if you require continuous, long-term heart rate monitoring and data collection for at-risk cardiac patients in an outpatient or remote setting. This wearable solution is best suited for ongoing patient management, providing clinicians with real-time physiologic trend data, automatic episode storage, and alert-based notifications for proactive care.
View ASSURE Wearable ECG →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Bunkerhill ECG-EF | ASSURE Wearable ECG |
|---|---|---|
| Pricing | Contact sales for pricing details. | Contact for pricing. |
| Deployment | Cloud-native platform (Carebricks) that integrates with existing health system infrastructure like EHRs. | Wearable device, mobile application, and cloud-based remote patient data platform. |
| FDA Status | Yes AI-estimated | 1 AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Bunkerhill ECG-EFTool A is a software-only solution designed for seamless integration with existing EHRs and clinical archives, analyzing routine 12-lead ECG data. This approach minimizes disruption to current clinical workflows and reduces the need for new device management or patient-side logistics.
Clinical Value
Bunkerhill ECG-EFTool A provides a specific, FDA-cleared diagnostic insight by detecting reduced Left Ventricular Ejection Fraction (LVEF u2264 40%) from routine ECGs, directly aiding in the early identification of heart failure. This offers a clear and actionable clinical utility, supported by validation studies. Tool B, while valuable for continuous monitoring, primarily focuses on data collection and trend analysis rather than a direct diagnostic output like LVEF.
Pricing & Value
TieBoth tools require direct contact for pricing information, making a head-to-head comparison of their cost-effectiveness or overall value proposition impossible based on the provided data.
Enterprise Readiness
Bunkerhill ECG-EFBoth tools are FDA-cleared, HIPAA compliant, and offer BAAs, establishing foundational readiness. However, Tool A's software-only deployment and seamless integration with existing EHRs, coupled with robust infrastructure security and business continuity plans, suggest a simpler and more scalable implementation for large healthcare systems compared to managing a wearable device ecosystem.
Innovation
Bunkerhill ECG-EFTool A leverages 'Generative AI for clinical reasoning and action' to derive a critical diagnostic parameter (LVEF) from a widely available, routine test (ECG), representing a significant advancement in AI-driven diagnostics. While Tool B innovates in wearable technology and artifact reduction, Tool A's application of advanced AI for specific diagnostic insight is arguably more disruptive.
Support & Docs
ASSURE Wearable ECGWhile neither tool provides extensive public documentation for enterprise-level support, Kestra Medical Technologies (Tool B) explicitly offers an ASSURE Helpline for providers and utilizes patient service representatives for patient training and support, indicating a more structured approach to user assistance.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Bunkerhill ECG-EF | ASSURE Wearable ECG |
|---|---|---|
| Name | Bunkerhill ECG-EF | ASSURE Wearable ECG |
| Company | BunkerHill Health | Kestra Medical Technologies |
| Description | An FDA-cleared artificial intelligence algorithm that detects reduced left ventricular ejection fraction (LVEF u2264 40%) from routine 12-lead electrocardiograms (ECGs), aiding in the early identification of patients at risk for heart failure. | A non-therapeutic device for continuous heart rate monitoring and data collection, integrated into their digital healthcare platform for at-risk cardiac patients. |
| Key Functionality | AI algorithm to detect reduced Left Ventricular Ejection Fraction (LVEF u2264 40%) from routine 12-lead ECG data. | Wearable ECG device for continuous heart rate monitoring with Quad Channel Processingu2122 and Adaptive Patient Intelligenceu2122 for filtering motion artifacts. |
| Categories | Cardiology AI | Cardiology AI, Wearables & Remote Monitoring (RPM) |
| Specialties | Cardiology, Emergency Medicine, Internal Medicine, Primary Care, Radiology | Cardiology |
Videos
Demos, reviews, and walkthroughs featuring Bunkerhill ECG-EF and ASSURE Wearable ECG.